medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2020, Number 4

<< Back Next >>

Medicina & Laboratorio 2020; 24 (4)

Factors involved in adherence to sublingual and subcutaneous immunotherapy in patients from the Allergy Service at a health institution in Medellin-Colombia

Acevedo-Vásquez AM, Farfán-Plata R, Ramírez-Giraldo R, Cardona-Villa R

Language: Spanish
References: 27
Page: 307-316
PDF size: 198.07 Kb.


ABSTRACT

Introduction. Allergic diseases in the world have increased in the last century, requiring novel treatments to improve the quality of life of patients. As a result, immunotherapy has emerged as a therapeutic option. The aim of this study was to identify aspects of adherence to sublingual (SLIT) and subcutaneous (SCIT) immunotherapy and reasons for non-adherence. Materials and methods. We present a retrospective study of patients with allergic diseases (rhinitis, asthma or atopic dermatitis) who initiated SCIT or SLIT at the allergology clinic in a health institution in Medellin, Colombia. Absolute and relative distributions, descriptive statistics and Chi square test were used for statistical analysis. Results. A total of 144 patients were selected (SCIT=84.7%; SLIT=15.3%). From the total of patients, 38.9% were considered adherent; no significant differences were found in adherence according to the route of administration (p=0.833). The most important reason for selecting the type of immunotherapy was medical recommendation. Of the non-adherent patients, 95.5% (n=84) discontinued the treatment. Sociodemographic characteristics of the two immunotherapy groups were relatively similar, with no significant differences. A significant difference was found between the service provided by the health institution and discontinuation of treatment, being greater for the group treated with SLIT (38.5%; p=0.007). Conclusion. The main cause of discontinuation of immunotherapy was the lack of approval for funding by the Health Promoting Agencies (53.6%).


REFERENCES

  1. Peterson B, Saxon A. Global increases in allergic respiratory disease: the possible role of diesel exhaust particles. Ann Allergy Asthma Immunol 1996;77:263-270. https://doi. org/10.1016/S1081-1206(10)63318-2.

  2. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996;9:636-642. https:// doi.org/10.1183/09031936.96.09040636.

  3. Maziak W, Behrens T, Brasky TM, Duhme H, Rzehak P, Weiland SK, et al. Are asthma and allergies in children and adolescents increasing? Results from ISAAC phase I and phase III surveys in Munster, Germany. Allergy 2003;58:572-579. https://doi.org/10.1034/ j.1398-9995.2003.00161.x.

  4. Meltzer EO, Blaiss MS, Derebery MJ, Mahr TA, Gordon BR, Sheth KK, et al. Burden of allergic rhinitis: results from the pediatric allergies in America survey. J Allergy Clin Immunol 2009;124:S43-70. https://doi.org/10.1016/j. jaci.2009.05.013.

  5. Weidinger S, Novak N. Atopic dermatitis. Lancet 2016;387:1109-1122. https://doi.org/10.1016/ S0140-6736(15)00149-X.

  6. Jang HJ, Hwang S, Ahn Y, Lim DH, Sohn M, Kim JH. Family quality of life among families of children with atopic dermatitis. Asia Pac Allergy 2016;6:213-219. https://doi.org/10.5415/apallergy. 2016.6.4.213.

  7. Tortajada-Girbés M, Mesa Del Castillo M, Larramona H, Lucas JM, Álvaro M, Tabar AI, et al. Evidence in immunotherapy for paediatric respiratory allergy: Advances and recommendations. Allergol Immunopathol 2016;44(Suppl1):1-32. https://doi. org/10.1016/j.aller.2016.09.001.

  8. Claes C, Mittendorf T, Graf von der Schulenburg JM. [Persistence and frequency of prescriptions of subcutaneous allergen-specific immunotherapy (SCIT) prescribed within the German statutory health insurance]. Med Klin (Munich) 2009;104:536-542. https://doi. org/10.1007/s00063-009-1113-8.

  9. Bahceciler NN, Galip N. Comparing subcutaneous and sublingual immunotherapy: what do we know? Curr Opin Allergy Clin Immunol 2012;12:640-647. https://doi.org/10.1097/ ACI.0b013e328358d5f2.

  10. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010:CD001186. https:// doi.org/10.1002/14651858.CD001186.pub2.

  11. Bender BG, Oppenheimer J. The special challenge of nonadherence with sublingual immunotherapy. J Allergy Clin Immunol Pract 2014;2:152-155. https://doi.org/10.1016/j. jaip.2014.01.003.

  12. Reisacher WR, Visaya JM. Patient adherence to allergy immunotherapy. Curr Opin Otolaryngol Head Neck Surg 2013;21:256-262. https:// doi.org/10.1097/MOO.0b013e32835f8048.

  13. Kiel MA, Roder E, Gerth van Wijk R, Al MJ, Hop WC, Rutten-van Molken MP. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol 2013;132:353-360. https://doi.org/10.1016/j. jaci.2013.03.013.

  14. Hsu NM, Reisacher WR. A comparison of attrition rates in patients undergoing sublingual immunotherapy vs subcutaneous immunotherapy. Int Forum Allergy Rhinol 2012;2:280-284. https://doi.org/10.1002/alr.21037.

  15. Stokes SC, Quinn JM, Sacha JJ, White KM. Adherence to imported fire ant subcutaneous immunotherapy. Ann Allergy Asthma Immunol 2013;110:165-167. https://doi.org/10.1016/j. anai.2012.11.010.

  16. Passalacqua G, Baiardini I, Senna G, Canonica GW. Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis. Clin Exp Allergy 2013;43:22-28. https://doi. org/10.1111/j.1365-2222.2012.04052.x.

  17. Bousquet J, Demoly P. Compliance and convenience to immunotherapy. Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess 2009;96:289-295.

  18. Koberlein J, Kothe AC, Schaffert C. Determinants of patient compliance in allergic rhinoconjunctivitis. Curr Opin Allergy Clin Immunol 2011;11:192-199. https://doi.org/10.1097/ ACI.0b013e3283466fcb.

  19. Antico A. Long-term adherence to sublingual therapy: literature review and suggestions for management strategies based on patients’ needs and preferences. Clin Exp Allergy 2014;44:1314- 1326. https://doi.org/10.1111/cea.12362.

  20. Pitsios C, Dietis N. Ways to increase adherence to allergen immunotherapy. Curr Med Res Opin 2019;35:1027-1031. https://doi.org/10.1 080/03007995.2018.1552044.

  21. Manzotti G, Riario-Sforza GG, Dimatteo M, Scolari C, Makri E, Incorvaia C. Comparing the compliance to a short schedule of subcutaneous immunotherapy and to sublingual immunotherapy during three years of treatment. Eur Ann Allergy Clin Immunol 2016;48:224-227.

  22. Lemberg ML, Berk T, Shah-Hosseini K, Kasche EM, Mosges R. Sublingual versus subcutaneous immunotherapy: patient adherence at a large German allergy center. Patient Prefer Adherence 2017;11:63-70. https://doi. org/10.2147/PPA.S122948.

  23. Sieber J, De Geest S, Shah-Hosseini K, Mosges R. Medication persistence with long-term, specific grass pollen immunotherapy measured by prescription renewal rates. Curr Med Res Opin 2011;27:855-861. https://doi.org/10.118 5/03007995.2011.559538.

  24. Lombardi C. What is the factor that improves adherence to allergen-specific immunotherapy? A secretary! Ann Allergy Asthma Immunol 2015;114:530-531. https://doi.org/10.1016/j. anai.2015.03.013.

  25. Leader BA, Rotella M, Stillman L, DelGaudio JM, Patel ZM, Wise SK. Immunotherapy compliance: comparison of subcutaneous versus sublingual immunotherapy. Int Forum Allergy Rhinol 2016;6:460-464. https://doi. org/10.1002/alr.21699.

  26. Schmitt J, Schwarz K, Stadler E, Wüstenberg EG. Allergy immunotherapy for allergic rhinitis effectively prevents asthma: Results from a large retrospective cohort study. J Allergy Clin Immunol 2015;136:1511-1516. https://doi. org/10.1016/j.jaci.2015.07.038.

  27. Jutel M, Brüggenjürgen B, Richter H, Vogelberg C. Real-world evidence of subcutaneous allergoid immunotherapy in house dust mite-induced allergic rhinitis and asthma. Allergy 2020;75:2046- 2054. https://doi.org/10.1111/all.14240.




2020     |     www.medigraphic.com